Qiang Liu

Title: Professor
Email: liuqiang@dlmedu.edu.cn
Major: Biochemistry and Molecular Biology

Education/Working Experience  

1989 Nanjing University, P. R. China, B.S.

 

1997 University of Illinois at Urbana-Champaign, Ph.D.

 

1998 University of Illinois at Urbana-Champaign, Postdoc

 

2000 University of Illinois at Chicago, M.D

 

2003 Mount Sinai hospital, New York, Resident

 

2006 Harvard Medical School, Research Fellow

 

Participation in the Academic Community  

1 Editor       Chinese Journal of Cancer; Frontiers in Bioscience ; Brain, Behavior, and Immunity (BBI)  

2 Co-chair     Asia-Pacific Alliance of Cancer Research

3 Director      Immunology Section of Chinese Association Pathophysiology

4 Reviewer     Cancer Research; Molecular Cell Biology; Oncogene; Proceedings of the National Academy of Sciences

5 Member    American Society of Hematology (ASH) ;American Society of Cell Biology (ASCB) ; American Association of Cancer Research (AACR)

 

Publication  

1. Zheng F, Yue C, Li G, He B, Cheng W, Wang X, Yan M, Long Z, Qiu W, Yuan Z, Xu J, Liu B, Shi Q, Lam EW, Hung MC,Liu Q*(2016). Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype. Nat Commun. (IF: 10.742). 19;7:10180.

2. Zhou W, Xu J, Gelston E, Wu X, Zou Z, Wang B, Zeng Y, Wang H, Liu A, Xu L, Liu Q*(2015). Inhibition of Bcl-xL overcomes polyploidy resistance and leads to apoptotic cell  death in acute myeloid leukemia cells. Oncotarget. (IF: 6.627).6(25):21557-71.

3. Hou Z J, Luo X, Zhang W, Peng F, Cui B, Wu S J, Zheng F M, Xu J, Xu L Z, Long Z J, Wang X T, Li G H, Wan X Y, Yang Y L, Liu Q*(2015). Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells. Oncotarget. (IF: 6.627).6(8):6326-6340.

4. Niu D G, Peng F, Zhang W, Guan Z, Zhao H D, Li J L, Wang K L, Li T T, Zhang Y, Zheng F M, Xu F, Han Q N, Gao P, Wen Q P, Liu Q*.(2015).Morphine promotes cancer stem cell properties, contributing to chemoresistance in breast cancer. Oncotarget.(IF: 6.627). 6(6):3963-3976.

5. Guan Z, Zhang J, Wang J, Wang H, Zheng FM, Peng J, Xu Y, Yan M, Liu B, Cui B, Huang Y and Liu Q*. (2014). SOX1 Down-regulates beta-catenin and Reverses Malignant Phenotype in Nasopharyngeal Carcinoma. Mol Cancer. (IF: 5.134). 13(1):257.

6. Yan M, Zhang Y, He B, Xiang J, Wang ZF, Zheng FM, Xu J, Chen MY, Zhu YL, Wen HJ, Wan XB, Yue CF, Yang N, Zhang W, Zhang JL, Wang J, Wang Y, Li LH, Zeng YX, Lam EW, Hung MC, Liu Q*. (2014). IKKα restoration via EZH2 suppression induces nasopharyngeal carcinoma differentiation. Nat Commun. (IF: 10.742). 5:3661.

7. Xu LZ, Long ZJ, Peng F, Liu Y, Xu J, Wang C, Jiang L, Guo T, Kamran M, Li SS, Wang CL, Wang HJ, Zhao YF, Wan XY, Liu Q*. (2014). Aurora Kinase A Suppresses Metabolic Stress-Induced Autophagic Cell Death by Activating mTOR Signaling in Breast Cancer Cells. Oncotarget. (IF: 6.627). 5(17):7498-511.

8. Wang J, Huang Y, Guan Z, Zhang JL, Su HK, Zhang W, Yue CF, Yan M, Guan S, Liu Q*. (2014). E3-ligase Skp2 predicts poor prognosis and maintains cancer stem cell pool in nasopharyngeal carcinoma. Oncotarget. (IF: 6.627). 5(14):5591-601.

9. Zheng FM, Long ZJ, Hou ZJ, Luo Y, Xu LZ, Xia JL, Lai XJ, Liu JW, Wang X, Kamran M, Yan M, Shao SJ, Lam EW, Wang SW, Lu G, Liu Q*. (2014). A Novel Small Molecule Aurora Kinase Inhibitor Attenuates Breast Tumor Initiating Cells and Overcomes Drug Resistance. Mol Cancer Ther. (IF: 6.107). 13(8):1991-2003.

10. Liu LL, Long ZJ, Wang LX, Zheng FM, Fang ZG, Yan M, Xu DF, Chen JJ, Wang SW, Lin DJ, Liu Q*. (2013). Inhibition of mTOR pathway sensitizes acute myeloid leukemia cells to aurora inhibitors by suppression of glycolytic metabolism. Mol Cancer Res. (IF: 4.353). 11(11):1326-36.

11. Zou ZZ, Yuan Z, Zhang Q, Long ZJ, Chen J, Tang Z, Zhu Y, Chen S, Xu J, Yan M, Wang J, Liu Q*. (2012). Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells. Autophagy. (IF: 12.042). 8(12):1798-810.

12. Zhou WH, Tang F, Xu J, Wu X, Yang SB, Feng ZY, Ding YG, Wan XB, Guan Z, Li HG, Lin DJ, Shao CK, Liu Q*.(2012). Low expression of Beclin 1, associated with high Bcl-xL, predicts a malignant phenotype and poor prognosis of gastric cancer.  Autophagy. (IF: 12.042). 8(3):389-400.

13. Xu J, Wan XB, Huang XF, Chan KC, Hong MH, Wang LH, Long ZJ, Liu Q, Yan M, Lo YM, Zeng YX, Liu Q*. (2010). Serologic antienzyme rate of Epstein-Barr virus DNase-specific neutralizing antibody segregates TNM classification in nasopharyngeal carcinoma. J Clin Oncol. (IF: 18.038). 28(35):5202-9.

14. Wan XB, Fan XJ, Chen MY, Xiang J, Huang PY, Guo L, Wu XY, Xu J, Long ZJ, Zhao Y, Zhou WH, Mai HQ, Liu Q*, Hong MH. (2010). Elevated Beclin 1 expression is correlated with HIF-1alpha in predicting poor prognosis of nasopharyngeal carcinoma. Autophagy. (IF: 12.042). 6(3):395-404.

15. Wang LH, Xiang J, Yan M, Zhang Y, Zhao Y, Yue CF, Xu J, Zheng FM, Chen JN, Kang Z, Chen TS, Xing D, Liu Q*. (2010). The mitotic kinase Aurora-A induces mammary cell migration and breast cancer metastasis by activating the Cofilin-F-actin pathway. Cancer Res. (IF: 8.650). 70(22):9118-28.

16. Yao JE, Yan M, Guan Z, Pan CB, Xia LP, Li CX, Wang LH, Long ZJ, Zhao Y, Li MW, Zheng FM, Xu J, Lin DJ, Liu Q*. (2009). Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival. Mol Cancer. (IF: 5.134). 8:95.

17. Xu DZ, Geng QR, Long ZJ, Zhan YQ, Li W, Zhou ZW, Chen YB, Sun XW, Chen G, Liu Q*. (2009). Positive lymph node ratio is an independent prognostic factor in gastric cancer after d2 resection regardless of the examined number of lymph nodes. Ann Surg Oncol. (IF: 4.120). 16(2):319-26.

 

Research Projects/Grants  

1 Natural Science Foundation of China (NSFC),Micro-fluidic chip-based functional and mechanistic study of tumor microenviroment in AURKA,2016-2019

2 Innovative Research Team in University from the Ministry of Education of China , Intervention study of signaling transduction in breast cancer stem cells, 2014-2016

3 National Basic Research Program of China (973), Dynamic evolution and intervention study of breast cancer stem cells,2012-2016

4   Key Program of Natural Science Foundation of China, Resistant mechanism of polyploidy cells induced by cancer target therapy,2012-2016

 

Admission Plan/Requirements  

Admission plan: 1 person.

Requirements: 1.Candidates must have proficiency in verbal and written English.

                     2. This position is ideally suited for those interested in cancer research.